# ASCENT (NCT02574455)

> Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02574455
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Gilead Sciences
- Conditions: Breast Cancer
- Interventions: Sacituzumab govitecan; Eribulin; Capecitabine; Gemcitabine; Vinorelbine
- Enrollment: 529
- Primary outcome: Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population

## Indexed commentary on ASCENT so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=ascent-nct02574455
